Infertility affects thousands of couples internationally, leaving a profound effect on their families and communities. According to the World Health Organization (WHO), approximately one out of six individuals of reproductive age worldwide experiences infertility in their life span. Approximately 35% of infertile couples are affected by male factor infertility, in which semen analysis is the gold standard diagnostic procedure. Oxidative stress (OS) is considered to play a pivotal role in the pathogenesis of male infertility. A thorough literature search was conducted in PubMed/MEDLINE, Scopus and Google Scholar databases, using MeSH terms and free-text keywords, to retrieve eligible articles published in the last decade, focusing on the potential beneficial role of oral antioxidants in male infertility. Antioxidant supplementation appears to improve the majority of sperm parameters. Therefore, antioxidant therapy is emerging as a promising aid in addressing male infertility. The purpose of this comprehensive literature review is to evaluate the significance of antioxidant supplementation in improving sperm parameters. Most of the included randomized controlled trials demonstrated the positive effects of oral antioxidants in various parameters, such as sperm concentration, total sperm count, motility and progressive motility. Consequently, pregnancy outcomes were evaluated, and increased pregnancy rates were reported in the majority of the included studies.
23 October 2026 in The Egyptian Journal of Internal Medicine
Background: Gestational diabetes mellitus (GDM) is a common pregnancy complication, with an estimated global prevalence of up to 14%. While lifestyle and genetic risk factors for GDM are well documented, the effect of probiotic supplementation on the management of GDM-specifically through the reduction of insulin resistance as measured by the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) index-has not been systematically evaluated. Objective: This meta-analysis aimed to quantitatively evaluate the clinical efficacy of probiotic supplementation in reducing the HOMA-IR index in a population of pregnant women with diagnosed GDM who manage the disease without the use of antidiabetic pharmacotherapy (insulin or oral agents), as well as to address the probiotics as an evidence-based, adjunctive therapeutic strategy for a more effective regulation of the metabolic profile during pregnancy. Methods: PubMed, Scopus, and Cochrane databases were searched for original research articles published up to August 10, 2025, which could potentially evaluate the impact of oral probiotic supplementation to the reduction of the HOMA-IR insulin resistance index in pregnant women with GDM without antidiabetic medication during the current pregnancy. A random-effects model was applied to estimate weighted mean differences (MDs) and 95% confidence intervals (CIs). Results: Four randomized controlled trials comprising 245 women (128 in the probiotic group and 126 in the placebo group) were included. The meta-analysis demonstrated a statistically significant reduction in the HOMA-IR levels in the intervention group compared to the control group (weighted MD: -0.51, 95% CI: -0.90 to -0.11, p = 0.01). Significant heterogeneity was observed among the studies (I 2 = 61.3%). Conclusion: The administration of probiotics appears to improve insulin sensitivity in women with GDM and may serve as a useful adjunctive therapy.